Akums Drugs And Pharmaceuticals Limited · NSE:AKUMS
Akums Drugs And Pharmaceuticals — Q1 FY27 Earnings Presentation
19 slides from Akums Drugs And Pharmaceuticals's earnings presentation, Aug 8, 2026
Slide 1: Regulation 30 disclosure cover letter to exchanges
Ref: Akums/Exchange/2026-27/39 August 08, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 T
Slide 2: Q1 FY 26-27 Investor Presentation
Q1 FY 26-27 Investor Presentation August 2026
Slide 3: Disclaimer
Disclaimer Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The co
Slide 4: Managing Directors' Message
Managing Directors’ Message Dear Investors We are pleased to announce the results for Q1 FY27. We have begun FY27 on a strong and encouraging note. We registered a healthy revenue growth of over 13% with EBIDTA increasing by more than 30%. The growth was primarily led by CDMO segment characterized b
Slide 5: More than Two Decades' Legacy of Expertise, Experience & Trust
More than Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Acquired Established R&D lab in Mumbai to Parabolic Drugs to manufacturing site for Launched Akumentis to venture into regul
Slide 6: Technologically Advanced Manufacturing Capabilities
Technologically Advanced Manufacturing Capabilities Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity (Cr units) 649 15 39 264 6 269 2.635 732 17 392 41 Ayurvedic / β-lac
Slide 7: R&D Focus
R&D Focus Illustrative Tablet Bi-layered, Inlay Multiple Tablets Pre-filled In Tablet Sustained Release Tablet in Capsule syringes Tablet in Tablet Lyophilized Smart Gummies Mouth Melting Tri Layered Vials Tablets Powders in Sachet Tablet Innovative In-house Technologies (1) As of 31st March 2025 6
Slide 8: Oriflame – Manufacturing business Acquisition
Oriflame – Manufacturing business Acquisition Rationale for Acquisition Transaction Overview Favorable Market Dynamics: • Acquisition of Manufacturing business of • Indian cosmetics market is fast growing Oriflame India for Rs 56 Cr • Multiple growth drivers including rise in • Transaction includes
Slide 9: Key drivers as well as their trends during Q1 FY27
Key drivers as well as their trends during Q1 FY27 Key drivers and their impact on Akums’ performance Strong CDMO Losses in Trade Muted API prices saw volume growth generics and performance in an increase in momentum API business Marketing Q1 continues curtailed segments Akums continued to witness A
Slide 10: Financial Performance Highlights
Q1 FY 27 Financial Performance Highlights 9
Slide 11: Q1 FY27 Performance Highlights
Q1 FY27 Performance Highlights Consolidated Performance Segment Break-up Business Vertical Share in revenue 205 cr 101 cr CDMO 82.6% 1,197 cr 121 cr 54 cr 1,050 cr 17.1% 8.4% Domestic Branded Formulation 9.9% 11.6% 5.1% Total Income EBITDA (including PAT International Branded Formulation 3.0% Total
Slide 12: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs Cr) Q1 FY27 Q1 FY26 Y-O-Y (%) Q4 FY26 Q-O-Q (%) Revenue 1,167 1,024 13.9% 1,158 0.8% COGS 645 582 10.9% 660 (2.3)% GP Margin % 44.7% 43.2% 43.0% Employee Expenses 201 176 14.4% 199 1.2% Other Expenses 145 137 5.9% 147 -1.1% EBITDA 175 129 35.4% 152 15.1% EBI
Slide 13: Quarterly Performance Trends
Quarterly Performance Trends Revenue (INR Cr.) EBITDA (INR Cr) Adjusted PAT (INR Cr) Margin % Margin % 12.6% 9.3% 12.7% 13.1% 15.0% 6.2% 4.1% 7.2% 7.0% 8.4% 13.9% 35.4% 56.1 % 1,160 1,158 1,167 175 1,024 1,018 147 152 129 101 86 83 94 65 43 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q2 FY26 Q3
Slide 14: Revenue and Margin Deep-Dive – Quarterly
Revenue and Margin Deep-Dive – Quarterly Revenue (INR Cr.) EBIDTA % • Revenue growth driven by CDMO • Other exp benefitted from operating leverage • Marketing segments muted in this quarter • GM improvement led by CDMO and API segments • Reduction in API and Trade generics in line with expectation 1
Slide 15: Segmental Quarterly Performance
Segmental Quarterly Performance Domestic Branded International Branded Trade CDMO Revenue API Revenue Formulation Revenue Formulation Revenue Generics Revenue QoQ 1.3% YoY 18.6% QoQ 12.9% YoY 7.3% QoQ -3.6% YoY -1.5% QoQ -23.4% YoY -9.5% QoQ -22.3% YoY -29.7% 952 964 27 45 813 115 23 41 107 102 21 3
Slide 16: Objects of the offer
Objects of the offer Amount as per offer Utilization as on June Objects (INR Cr) Unutilized Amount document 30, 2026 Repayment borrowings of Akums 159.91 159.91 - Repayment of borrowings of our 227.09 227.09 - Subsidiaries Funding incremental working capital 55.00 55.00 - requirements of our Company
Slide 17: Annexures
Annexures ‘bel lids
Slide 18: Abbreviations and Definitions
Abbreviations and Definitions Abbreviations Definitions • CDMO: Contract development and manufacturing organization • Adj EBITDA: Profit before tax + finance cost + depreciation and amortization + Exceptional items – other income • API: Active Pharmaceutical Ingredient • Adj PAT: PAT + Exceptional i
Slide 19: Thank You
Thank You For further information, contact: IR Desk Akums Drugs and Pharmaceuticals Ltd Email: [email protected]/[email protected] 18
Akums Drugs and Pharmaceuticals — Q1 FY27 Earnings Presentation on 6ix